SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CALABRO', Luana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.334
AS - Asia 3.198
EU - Europa 1.117
SA - Sud America 594
Continente sconosciuto - Info sul continente non disponibili 120
AF - Africa 73
OC - Oceania 4
Totale 8.440
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.124
SG - Singapore 1.243
IT - Italia 454
CN - Cina 448
BR - Brasile 440
VN - Vietnam 402
HK - Hong Kong 370
BD - Bangladesh 277
DE - Germania 119
FR - Francia 99
GB - Regno Unito 99
JP - Giappone 99
ID - Indonesia 97
CA - Canada 93
RU - Federazione Russa 92
IN - India 85
FI - Finlandia 77
MX - Messico 72
AR - Argentina 59
NL - Olanda 34
ZA - Sudafrica 32
UA - Ucraina 28
TR - Turchia 26
IQ - Iraq 25
PL - Polonia 23
EC - Ecuador 21
AT - Austria 19
VE - Venezuela 18
CO - Colombia 17
PH - Filippine 17
ES - Italia 13
SA - Arabia Saudita 13
MY - Malesia 12
KR - Corea 11
PK - Pakistan 11
SE - Svezia 11
PY - Paraguay 10
AE - Emirati Arabi Uniti 9
CL - Cile 9
JM - Giamaica 9
LT - Lituania 9
JO - Giordania 8
MA - Marocco 8
BO - Bolivia 7
CR - Costa Rica 7
HN - Honduras 7
UY - Uruguay 7
CH - Svizzera 6
UZ - Uzbekistan 6
DZ - Algeria 5
EG - Egitto 5
KE - Kenya 5
GT - Guatemala 4
NP - Nepal 4
PA - Panama 4
PE - Perù 4
TN - Tunisia 4
TT - Trinidad e Tobago 4
AL - Albania 3
AU - Australia 3
BE - Belgio 3
BG - Bulgaria 3
BH - Bahrain 3
BY - Bielorussia 3
KZ - Kazakistan 3
PS - Palestinian Territory 3
PT - Portogallo 3
RS - Serbia 3
SV - El Salvador 3
AM - Armenia 2
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BN - Brunei Darussalam 2
DO - Repubblica Dominicana 2
EE - Estonia 2
ET - Etiopia 2
GA - Gabon 2
IL - Israele 2
KH - Cambogia 2
KW - Kuwait 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
MK - Macedonia 2
NI - Nicaragua 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
AO - Angola 1
BB - Barbados 1
BF - Burkina Faso 1
BJ - Benin 1
BS - Bahamas 1
CI - Costa d'Avorio 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
CZ - Repubblica Ceca 1
GE - Georgia 1
GM - Gambi 1
GN - Guinea 1
GR - Grecia 1
Totale 8.303
Salva come PNG Salva come JPEG
Città #
Singapore 680
Ashburn 542
San Jose 481
Santa Clara 463
Hong Kong 368
Council Bluffs 232
Ho Chi Minh City 146
Beijing 107
Hanoi 103
Tokyo 95
New York 84
Jakarta 74
Los Angeles 74
Lauterbourg 73
Helsinki 61
Milan 51
Mexico City 50
Chicago 43
Dallas 43
Chandler 40
São Paulo 40
Bologna 38
Toronto 35
London 31
Buffalo 29
Nuremberg 26
Rome 26
Salt Lake City 22
Orem 21
Munich 19
Warsaw 19
Da Nang 18
Ferrara di Monte Baldo 18
Hefei 18
Montreal 18
Phoenix 18
Falkenstein 17
Ferrara 17
Haiphong 17
Shanghai 17
Brooklyn 16
Denver 14
Hải Dương 14
Johannesburg 14
Atlanta 13
Brasília 13
Florence 13
New Delhi 13
San Francisco 13
Baghdad 12
Rio de Janeiro 12
Biên Hòa 11
Lappeenranta 11
Moscow 11
Naples 11
Seattle 11
Avon 10
Charlotte 10
Chennai 10
Elk Grove Village 10
Frankfurt am Main 10
Stockholm 10
Dhaka 9
Quito 9
Vienna 9
Amman 8
Boston 8
Düsseldorf 8
Guangzhou 8
Guayaquil 8
Paris 8
Turin 8
Amsterdam 7
Belo Horizonte 7
Figino 7
Houston 7
Kuala Lumpur 7
Montevideo 7
Mumbai 7
San José 7
Santiago 7
Ankara 6
Assago 6
Asunción 6
Buenos Aires 6
Bến Tre 6
Columbus 6
Curitiba 6
Fortaleza 6
Hounslow 6
Kingston 6
Manchester 6
Philadelphia 6
Poplar 6
Tampa 6
Yongsan-gu 6
Bogotá 5
Can Tho 5
Guarulhos 5
Hangzhou 5
Totale 4.792
Salva come PNG Salva come JPEG
Nome #
Peptide Receptor Radionuclide Therapy in Advanced Refractory Meningiomas: Efficacy and Toxicity in a Long Follow-up 187
Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge 178
A randomized phase II trial of Captem or Folfiri as second-line therapy in neuroendocrine carcinomas 170
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 158
A Multidisciplinary Approach to Improve the Management of Immune-Checkpoint Inhibitor-Related Pneumonitis 157
Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study 151
T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer 144
Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study 143
Bone metastases and immunotherapy in patients with advanced non-small-cell lung cancer 132
Avelumab Versus Docetaxel in Patients With Platinum-Treated Advanced NSCLC: 2-Year Follow-Up From the JAVELIN Lung 200 Phase 3 Trial 131
Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy 128
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial 125
Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy 118
P3.12.20 VAF of EGFR Mutations in Relation to Early Tumor Shrinkage or Deepness of Response During Osimertinib in NSCLC Patients 113
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC 109
Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival 105
Biomarkers for immune checkpoint inhibitors--authors' reply 105
Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial 105
Challenges in lung cancer therapy during the COVID-19 pandemic 104
Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014 104
Efficacy and Safety of Chemotherapy after Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer 103
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 102
Circulating haemopoietic and endothelial progenitor cells are decreased in COPD 102
Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications 102
Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies 100
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study 99
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study 98
Brief Communication PD1-related Nephrotoxicity: Optimizing Its Clinical Management Through Histopathologic Features 98
Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy 97
Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases 96
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015 96
The emerging role of cancer nanotechnology in the panorama of sarcoma 94
Cancer bio‑immunotherapy XVI annual NIBIT‑(Italian Network for Tumor Biotherapy) meeting, October 11–13 2018, Milan, Italy 93
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation 91
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center 89
CD40 expression by human melanocytic lesions and melanoma cell lines and direct CD40 targeting with the therapeutic anti-CD40 antibody CP-870.893 88
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study 87
Prognostic and Predictive Role of Body Composition in Metastatic Neuroendocrine Tumor Patients Treated with Everolimus: A Real-World Data Analysis 85
SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines 84
COVID and Lung Cancer 84
First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial 81
Weekly docetaxel vs. docetaxel-based combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer patients. The DISTAL-2 randomized trial 81
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 79
Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 78
Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013 76
Quality of Life Analysis of TORCH, a Randomized Trial Testing First-Line Erlotinib Followed by Second-Line Cisplatin/Gemcitabine Chemotherapy in Advanced Non-Small-Cell Lung Cancer 76
Markers of endothelial and platelet status in patients with essential thrombocytemia and polycythemia vera 76
Profilo lipidico nelle neoplasie ematologiche [Lipid profile in haematological malignancies] 74
Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme 74
Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications 73
Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: immunotherapeutic implication 70
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy 70
The future of mesothelioma treatment: time to shift gear 70
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 69
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study 69
Primary hepatic epithelioid hemangioendothelioma progressively responsive to Interferon-alpha: is there room for novel anti-angiogenetic treatments? 69
Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy 69
Increased concentration of circulating acid glycosaminoglycans in chronic lymphocytic leukemia and essential thrombocytaemia 69
Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme 68
Differential levels of solubile angiopoietin-2 and Tie-2 in patients with haematological malignancies 68
Enforced expression of KDR receptor promotes proliferation, survival and megakaryocytic differentiation of TF1 progenitor cell line 68
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial 68
Differential levels of solubile Endoglin (CD105) in myeloid malignancies 67
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 66
Ipilimumab experience in heavily pre-treated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy) 66
L'ipersplenismo: Attualità e prospettive [Hypersplenism: Current status and perspectives] 66
Lymphocytes from patients with early stage of B-cell chronic lymphocytic leukaemia and long survival synthesize decorin 65
Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells 64
Methimazole-induced agranulocytosis and quick recovery with G-CSF: case report 64
Immune checkpoint blockade in malignant mesothelioma: A novel therapeutic strategy against a deadly disease? 62
DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy 61
Soluble angiogenic factors: implications for chronic myeloproliferative disorders 60
High levels of exosomes expressing CD63 and caveolin-1 in plasma of melanoma patients 59
Levels of solubile angiogenin in chronic myeloid malignancies: clinical implications 59
Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases 59
Italian cohort of nivolumab Expanded Access Programme (EAP): efficacy and safety data from a real-world population 58
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 58
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012 57
Epigenetically regulated clonal heretability of CTA expression profiles in human melanoma 57
Epigenetic immunomodulation of hematopoietic malignancies 56
Immune-Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era 55
Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma 55
Seventh annual meeting of the Italian Network for Tumor Biotherapy (NIBIT) 54
Expression and regulation of the B7-H3 receptor in human mesothelial and mesothelioma cells: a novel target for immunotherapeutic applications 54
Immunophenotypic features of acute myeloid leukemias overexpressing the interleukin 3 receptor alpha chain 54
Targeting of HLA-DR molecules transduces agonistic functional signals in Cutaneous melanoma 54
Thymosin α1 in melanoma from the clinical trial setting to the daily practice and beyond 52
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies 51
Clinical studies with anti-CTLA-4 antibodies in non-melanoma indications 51
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 49
CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy? 49
Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): Results from the global, double-blind, placebo-controlled DETERMINE study 47
Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial 47
The Effects of Variant Allele Frequency for EGFR Mutation on Early Tumor Shrinkage and Deepness of Response to Osimertinib in Patients with Metastatic Non-Small Cell Lung Cancer: An Exploratory Analysis 44
Eighth annual meeting of the Italian network for tumor biotherapy (NIBIT), Siena, October 7-9, 2010 43
Italian Cohort of Nivolumab Expanded Access Program in Squamous Non-Small Cell Lung Cancer: Results from a Real-World Population 43
A prospective study on clinicians’ attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020) 42
Tenth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), SIENA, Italy, November 5-7, 2012 38
Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients 37
Diagnostic accuracy of 18F-FDG PET/CT in muscle-invasive bladder cancer: rationale and design of the MIBC-PET study 34
Totale 8.207
Salva come PNG Salva come JPEG
Categoria #
all - tutte 63.197
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 361
Totale 63.558
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/202234 0 0 0 0 0 0 0 0 0 0 0 34
2022/2023168 5 46 3 2 48 6 5 9 22 2 10 10
2023/2024260 10 47 21 13 19 4 4 15 9 13 20 85
2024/20251.877 81 125 172 29 237 234 67 53 198 398 173 110
2025/20265.341 370 206 484 614 672 184 563 309 499 625 501 314
2026/2027760 242 249 269 0 0 0 0 0 0 0 0 0
Totale 8.440